Vadolas Jim, Nualkaew Tiwaporn, Voon Hsiao P J, Vilcassim Shahla, Grigoriadis George
Centre for Cancer Research Hudson Institute of Medical Research Clayton Victoria Australia.
Department of Molecular and Translational Sciences Monash University Clayton Victoria Australia.
Hemasphere. 2024 May 15;8(5):e78. doi: 10.1002/hem3.78. eCollection 2024 May.
α-Thalassemia represents one of the most important genetic modulators of β-hemoglobinopathies. During this last decade, the ongoing interest in characterizing genotype-phenotype relationships has yielded incredible insights into α-globin gene regulation and its impact on β-hemoglobinopathies. In this review, we provide a holistic update on α-globin gene expression stemming from DNA to RNA to protein, as well as epigenetic mechanisms that can impact gene expression and potentially influence phenotypic outcomes. Here, we highlight defined α-globin targeted strategies and rationalize the use of distinct molecular targets based on the restoration of balanced α/β-like globin chain synthesis. Considering the therapies that either increase β-globin synthesis or reactivate γ-globin gene expression, the modulation of α-globin chains as a disease modifier for β-hemoglobinopathies still remains largely uncharted in clinical studies.
α地中海贫血是β血红蛋白病最重要的遗传调节因子之一。在过去十年中,对基因型-表型关系特征的持续研究,为α珠蛋白基因调控及其对β血红蛋白病的影响带来了惊人的见解。在这篇综述中,我们全面更新了从DNA到RNA再到蛋白质的α珠蛋白基因表达,以及可能影响基因表达并潜在影响表型结果的表观遗传机制。在这里,我们重点介绍了明确的α珠蛋白靶向策略,并基于恢复平衡的α/β样珠蛋白链合成,对不同分子靶点的使用进行了合理化分析。考虑到增加β珠蛋白合成或重新激活γ珠蛋白基因表达的疗法,在临床研究中,将α珠蛋白链作为β血红蛋白病的疾病修饰剂进行调节,在很大程度上仍未得到充分探索。